Amlodipine‐Based Therapy and Its Effect on Time in Target Range and Long‐Term Blood Pressure Variability Across Age Groups in Chinese Patients With Primary Hypertension: A Retrospective Study
The Journal of Clinical Hypertension · 2025
DOI: 10.1111/jch.70151 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Jinghan Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Amlodipine, Blood Pressure, Antihypertensive Agents, Hypertension. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Joint Fund for the Innovation of Science and Technology, Fujian Province.
Abstract (Originalsprache)
This study aimed to compare systolic blood pressure (SBP) time in target range (TTR), long‐term blood pressure (BP) variability (BPV), and BP control across age groups (18–45, 46–64, 65–79, ≥80 years) in patients with primary hypertension treated with amlodipine‐based antihypertensive therapy for ≥12 months. Data were obtained from adult patients enrolled in the China Hypertension Center who received amlodipine‐based antihypertensive therapy. Demographics, BP measurements, and laboratory results were recorded. Baseline characteristics, SBP TTR, long‐term BPV, and BP control were compared among age groups. A total of 36 153 patients were included: 2681 in the 18–45 group, 14 300 in the 46–64 group, 15 595 in the 65–79 group, and 3577 in the ≥ 80 group. Younger and middle‐aged patients demonstrated better indicator improvements. SBP TTR declined with age (82.52% ± 19.68%, 81.98% ± 20.69%, 79.10% ± 22.96%, and 78.33% ± 23.50%, respectively; p < 0.001). BP control also declined with age (84.04%, 83.20%, 80.44%, and 79.59%, respectively; p < 0.001). BPV increased with age, though not significantly ( p = 0.051). During follow‐up, SBP TTR and BP control improved, while BPV declined, with most changes reaching statistical significance. Across all age groups, SBP TTR remained above 78% throughout follow‐up. Long‐term continuous use of amlodipine is beneficial for achieving improved BP control, enhanced TTR, and reduced BPV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- The Higher Educational Key Laboratory For Cardiovascular Disease of Fujian Province; Clinical Research Center for Metabolic Heart Disease of Fujian Province; The First Affiliated Hospital, Fujian Medical University, Fuz…
- Peking University People's Hospital, Beijing, China.
ORCID-Profile: Ningling Sun, Jinxiu Lin
Förderung
- the Joint Fund for the Innovation of Science and Technology, Fujian Province
Zitieren
APA
Yang, J., Chen, S., Chai, D., Peng, F., Sun, N., & Lin, J. (2025). Amlodipine‐Based Therapy and Its Effect on Time in Target Range and Long‐Term Blood Pressure Variability Across Age Groups in Chinese Patients With Primary Hypertension: A Retrospective Study. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70151
Vancouver
Yang J, Chen S, Chai D, Peng F, Sun N, Lin J. Amlodipine‐Based Therapy and Its Effect on Time in Target Range and Long‐Term Blood Pressure Variability Across Age Groups in Chinese Patients With Primary Hypertension: A Retrospective Study. The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.70151
BibTeX
@article{Yang2025,
author = {Yang, Jinghan and Chen, Shuling and Chai, Dajun and Peng, Feng and Sun, Ningling and Lin, Jinxiu},
title = {Amlodipine‐Based Therapy and Its Effect on Time in Target Range and Long‐Term Blood Pressure Variability Across Age Groups in Chinese Patients With Primary Hypertension: A Retrospective Study},
journal = {The Journal of Clinical Hypertension},
year = {2025},
doi = {10.1111/jch.70151}
}
EUVIMED